More Accurate Markers Identified for Detecting Response to Epigenetic Drugs for Myelodysplastic Syndromes, University of Southern California Study

Published: Apr 08, 2013

Researchers have identified and validated two DNA methylation markers that could help physicians to more accurately determine a patient's response to epigenetic drugs for treatment of myelodysplastic syndromes (MDS), according to Xiaojing Yang, Ph.D., a postdoctoral fellow at the University of Southern California, Los Angeles, who presented the data at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.

Back to news